• Adipose–CXCL5 Crosstalk in PDAC Immune Evasion

  2026-09-15

  The reference study identifies an obesity-associated signaling route in which adipose-derived IL-1β and TNF stimulate PDAC cells to secrete CXCL5, limiting CD8 T-cell entry into tumors. Its combination of patient-derived conditioned media, transcriptomics, cytokine assays, CRISPR perturbation, and syngeneic mouse models supports CXCL5 as a context-dependent immune-evasion mediator and suggests that ligand depletion may need checkpoint blockade to reduce tumor burden.

• Pazopanib Hydrochloride: Mechanism & Assays

  2026-09-15

  Pazopanib Hydrochloride, also called GW786034, is a multi-target receptor tyrosine kinase inhibitor used in cancer research and approved for selected advanced cancers. Its kinase-panel activity supports anti-angiogenic studies, while orthogonal viability measurements are needed to distinguish growth inhibition from true cell killing.

• FGFR–TGFβ–PI3K/AKT Control of Periostin

  2026-09-14

  Labrèche et al. identify a context-dependent regulatory circuit in which FGFR, TGFβ, PKC, and PI3K/AKT signaling jointly control periostin expression in Neu-positive breast cancer cells. The study combines tumor models, human tissue microarrays, tumor-derived cell lines, and biochemical perturbation to show how epithelial tumor cells acquire a stromal-associated matrix program.

• Mitoxantrone Assays for ABCG2 Resistance

  2026-09-14

  Mitoxantrone BA2039 supports a practical workflow that connects topoisomerase II inhibition, intracellular drug exposure, ABCG2-mediated resistance, and apoptosis. This guide translates the marein–ABCG2 findings into reproducible viability, accumulation, combination, and troubleshooting strategies for oncology and carefully bounded antiviral research.

• Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

  2026-09-13

  This 2024 Journal of Ethnopharmacology study integrates network pharmacology with cellular and mouse models to examine how Shenqi Fuzheng injection affects glioma growth and migration. Its main contribution is the identification of the SRC/PI3K/AKT pathway as a candidate mechanistic axis linked to cell-cycle arrest, reduced migration, and slower tumor development.

• Ceftazidime: From Spectrum to Resistance Assays

  2026-09-12

  Ceftazidime is a third-generation cephalosporin with distinctive value in Pseudomonas aeruginosa and Gram-negative bacterial infection research. This guide connects its mechanism and handling requirements with genomic, plasmid-transfer, and susceptibility findings from a 2025 CREC study to improve assay interpretation.

• How Mixing Shapes mRNA LNP Performance

  2026-09-11

  This Nature Communications study isolates primary mixing as a major determinant of mRNA lipid nanoparticle physicochemical properties and biological performance. By comparing ten mixing approaches under otherwise controlled formulation conditions, it shows why manually prepared or laminar-flow particles may not predict products made with turbulent-flow equipment at manufacturing scale.

• SM-102: Reliable LNP and Cell Assay Workflows

  2026-09-11

  This scenario-based guide explains how SM-102 (SKU C1042) can support controlled lipid nanoparticle formulation and more interpretable downstream cell viability, proliferation, and cytotoxicity assays. It covers solvent compatibility, formulation controls, literature-based comparison, and practical supplier-selection criteria.

• SIRT1/2 Inhibitor IV: OGD/R Assay Guide

  2026-09-10

  Use SIRT1/2 Inhibitor IV (cambinol) to interrogate how SIRT1/2 activity connects metabolism, lactylation, STAT3 transport, acetylation, and cell survival. This workflow separates reference-supported biology from practical starting conditions for astrocyte OGD/R, cancer-cell apoptosis, and xenograft studies.

• Separating Growth Arrest from Cancer Cell Death

  2026-09-10

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measures capture different components of drug response. The framework supports more interpretable cancer assays by separating proliferative arrest from actual cell killing and by accounting for differences in response timing.

• Cabozantinib Workflows for RCC Signaling Studies

  2026-09-09

  Build sharper RCC and MTC experiments with Cabozantinib (XL184) by separating acute kinase suppression from chronic signaling adaptation. This workflow combines phosphoproteomics, migration, invasion, and endothelial assays to reveal both treatment response and resistance-associated phenotypes.

• DOT1L Inhibition Reprograms Immunity in Myeloma

  2026-09-09

  The reference study identifies DOT1L as a preferential epigenetic dependency in multiple myeloma and shows that its inhibition activates type I interferon and STING-associated innate immune signaling. Importantly, DOT1L inhibition enhanced lenalidomide responses by increasing interferon-regulated genes and suppressing IRF4-MYC signaling, providing a mechanistic basis for combination research.

• Biotin-HPDP for Reversible Thiol Labeling

  2026-09-08

  Biotin-HPDP is a sulfhydryl-reactive reagent for reversible labeling of accessible protein thiols. Its pyridyl disulfide chemistry connects biotin affinity capture with applications such as protein biotinylation for affinity purification and detection of S-nitrosylated proteins.

• Anlotinib in Desmoplastic Small Round Cell Tumor

  2026-09-08

  This case report describes radiographic regression of metastatic intra-abdominal desmoplastic small round cell tumor after anlotinib treatment, with fatigue and hypertriglyceridemia as manageable toxicities. Its main contribution is hypothesis-generating clinical evidence for a multi-target tyrosine kinase inhibitor in a rare sarcoma lacking standardized systemic therapy.

• Sunitinib: Multi-Targeted RTK Inhibitor

  2026-09-07

  Sunitinib is an orally bioavailable, multi-targeted receptor tyrosine kinase inhibitor that blocks VEGFR, PDGFR, KIT, and RET signaling. Its research value includes tumor angiogenesis assays, apoptosis induction in renal cell carcinoma, and cell cycle arrest at G0/G1 phase, while combination findings remain preclinical.

7426 records 1/496 page Next 12345 下5页 Last page